Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/104752
DC FieldValueLanguage
dc.contributor.authorHrynchak, Ivanna-
dc.contributor.authorSantos, Liliana-
dc.contributor.authorFalcão, Amílcar-
dc.contributor.authorGomes, Célia M.-
dc.contributor.authorAbrunhosa, Antero J.-
dc.date.accessioned2023-01-24T11:47:33Z-
dc.date.available2023-01-24T11:47:33Z-
dc.date.issued2021-10-04-
dc.identifier.issn1422-0067-
dc.identifier.urihttps://hdl.handle.net/10316/104752-
dc.description.abstractThe overexpression of human epidermal growth factor 2 (HER2) in breast cancer (BC) has been associated with a more aggressive tumor subtype, poorer prognosis and shorter overall survival. In this context, the development of HER2-targeted radiotracers is crucial to provide a non-invasive assessment of HER2 expression to select patients for HER2-targeted therapies, monitor response and identify those who become resistant. Antibodies represent ideal candidates for this purpose, as they provide high contrast images for diagnosis and low toxicity in the therapeutic setting. Of those, nanobodies (Nb) are of particular interest considering their favorable kinetics, crossing of relevant biological membranes and intratumoral distribution. The purpose of this review is to highlight the unique characteristics and advantages of Nb-based radiotracers in BC imaging and therapy. Additionally, radiolabeling methods for Nb including direct labeling, indirect labeling via prosthetic group and indirect labeling via complexation will be discussed, reporting advantages and drawbacks. Furthermore, the preclinical to clinical translation of radiolabeled Nbs as promising theranostic agents will be reported.pt
dc.language.isoengpt
dc.publisherMDPIpt
dc.relationFCT - PD/BDE/150331/2019pt
dc.relationFCT - PD/BDE/150707/2020pt
dc.rightsopenAccesspt
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt
dc.subjectnanobodiespt
dc.subjecttargeted radionuclide therapypt
dc.subjectHER2 breast cancerpt
dc.subjectradiolabeling strategiespt
dc.subjectnuclear imagingpt
dc.titleNanobody-Based Theranostic Agents for HER2-Positive Breast Cancer: Radiolabeling Strategiespt
dc.typearticlept
degois.publication.firstPage10745pt
degois.publication.issue19pt
degois.publication.titleInternational Journal of Molecular Sciencespt
dc.peerreviewedyespt
dc.identifier.doi10.3390/ijms221910745-
degois.publication.volume22pt
dc.date.embargo2021-10-04*
dc.identifier.pmid34639086-
uc.date.periodoEmbargo0pt
dc.identifier.eissn1422-0067-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypearticle-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.fulltextCom Texto completo-
item.languageiso639-1en-
crisitem.author.researchunitICNAS - Institute for Nuclear Sciences Applied to Health-
crisitem.author.researchunitICNAS - Institute for Nuclear Sciences Applied to Health-
crisitem.author.researchunitICNAS - Institute for Nuclear Sciences Applied to Health-
crisitem.author.orcid0000-0002-1671-7861-
crisitem.author.orcid0000-0003-2525-9572-
crisitem.author.orcid0000-0002-3854-6549-
crisitem.author.orcid0000-0002-7497-4129-
crisitem.author.orcid0000-0002-4145-854X-
Appears in Collections:I&D ICNAS - Artigos em Revistas Internacionais
I&D CIBIT - Artigos em Revistas Internacionais
I&D ICBR - Artigos em Revistas Internacionais
I&D CIBB - Artigos em Revistas Internacionais
Show simple item record

SCOPUSTM   
Citations

15
checked on Mar 25, 2024

WEB OF SCIENCETM
Citations

15
checked on Apr 2, 2024

Page view(s)

69
checked on Apr 9, 2024

Download(s)

96
checked on Apr 9, 2024

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons